Study of the Safety and Pharmacokinetics of KSP-1007 Alone and Coadministered With Meropenem in Healthy Subjects
Status:
Recruiting
Trial end date:
2022-07-07
Target enrollment:
Participant gender:
Summary
This study is a first-in-human, Phase 1, randomized, double- blind, four-part,
dose-escalation study to assess the safety, tolerability, and pharmacokinetics of single
(Part 1) and repeat (Part 2) escalating intravenous doses of KSP-1007. Repeated escalating
doses of KSP-1007 will be co-administered with meropenem (Part 3) and single, ascending doses
of KSP-1007 will be administered alone in healthy Japanese subjects (Part 4)